HER-2 AND INT-2 AMPLIFICATION ESTIMATED BY QUANTITATIVE PCR IN PARAFFIN-EMBEDDED OVARIAN-CANCER TISSUE SAMPLES

被引：37

作者：

HRUZA, C

DOBIANER, K

BECK, A

CZERWENKA, K

HANAK, H

KLEIN, M

LEODOLTER, S

MEDL, M

MULLAUERERTL, S

PREISER, J

ROSEN, A

SALZER, H

SEVELDA, P

SPONA, J

机构：

[1] UNIV VIENNA,DEPT OBSTET & GYNECOL 1,SPITALGASSE 23,E900,A-1090 VIENNA,AUSTRIA

[2] UNIV VIENNA,DEPT CELLULAR ENDOCRINOL,LUDWIG BOLTZMANN INST EXPTL ENDOCRINOL,A-1090 VIENNA,AUSTRIA

[3] HANUSCHKRANKENHAUS,INST PATHOL,A-1140 VIENNA,AUSTRIA

[4] HANUSCHKRANKENHAUS,DEPT OBSTET & GYNECOL,A-1140 VIENNA,AUSTRIA

[5] KRANKENHAUS STADT VIENNA LAINZ,DEPT OBSTET & GYNECOL,A-1130 VIENNA,AUSTRIA

[6] KRANKENHAUS STADT VIENNA LAINZ,INST PATHOL,A-1130 VIENNA,AUSTRIA

来源：

EUROPEAN JOURNAL OF CANCER | 1993年 / 29A卷 / 11期

关键词：

D O I：

10.1016/0959-8049(93)90301-U

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Competitive polymerase chain reaction (PCR) systems were developed for rapid and quantitative estimation of HER-2 (c-erbB-2) and INT-2 oncogene amplification in paraffin-embedded ovarian cancer tissue samples. The beta-globin gene was used as reference and DNA from paraffin-embedded placenta tissue as single copy control. Reliability of the PCR method could be demonstrated by comparing dot blot data with PCR data of identical tumour samples. The PCR method was used to determine HER-2 and INT-2 copy numbers in 196 ovarian cancer samples. HER-2 and INT-2 were found to be amplified in 40 and 19%, respectively. In 8% HER-2 copy numbers were greater than five, but no high INT-2 copies were noted. Kaplan-Meier estimates did not reveal significant association with overall survival. Indirect correlation between HER-2 and INT-2 amplification was observed. The present PCR system is a valuable method for prospective and retrospective studies.

引用

页码：1593 / 1597

页数：5

共 28 条

[1]

ADNANE J, 1989, ONCOGENE, V4, P1389

[2] AMPLIFICATION OF C-ERBB-2 AND AGGRESSIVE HUMAN-BREAST TUMORS [J].

ALI, IU ;

CAMPBELL, G ;

LIDEREAU, R ;

CALLAHAN, R .

SCIENCE, 1988, 240 (4860) :1795-1796

[3]

ALI IU, 1989, ONCOGENE, V4, P89

[4]

ALI IU, 1988, ONCOL RES, V3, P138

[5]

BABIAK J, 1992, CANCER, V70, P770, DOI 10.1002/1097-0142(19920815)70:4<770::AID-CNCR2820700409>3.0.CO

[6]

2-U

[7] ASSOCIATION OF INT2/HST1 COAMPLIFICATION IN PRIMARY BREAST-CANCER WITH HORMONE-DEPENDENT PHENOTYPE AND POOR PROGNOSIS [J].

BORG, A ;

SIGURDSSON, H ;

CLARK, GM ;

FERNO, M ;

FUQUA, SAW ;

OLSSON, H ;

KILLANDER, D ;

MCGURIE, WL .

BRITISH JOURNAL OF CANCER, 1991, 63 (01) :136-142

[8] CATHEPSIN D ASSAY IN PRIMARY BREAST-CANCER AND LYMPH-NODES - RELATIONSHIP WITH C-MYC, C-ERB-B-2 AND INT-2 ONCOGENE AMPLIFICATION AND NODE INVASIVENESS [J].

BROUILLET, JP ;

THEILLET, C ;

MAUDELONDE, T ;

DEFRENNE, A ;

SIMONYLAFONTAINE, J ;

SERTOUR, J ;

PUJOL, H ;

JEANTEUR, P ;

ROCHEFORT, H .

EUROPEAN JOURNAL OF CANCER, 1990, 26 (04) :437-441

[9]

CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO

[10]

2-Y

← 1 2 3 →